Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Halldin

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Anesthesia and Analgesia|December 1, 1989
Disposition kinetics of ropivacaine in humansA Lee, D Fagan, M Lamont, et al.
Biochemical Pharmacology|October 1, 1985
Stimulation of pheomelanogenesis in cultured B16 melanoma cells by 4-tertiary butylcatecholT Kawashima, M M Halldin, K Fukuyama, et al.
Journal of Inherited Metabolic Disease|August 22, 2014
Increased and early lipolysis in children with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency during fastC Bieneck Haglind, A Nordenström, S Ask, et al.
Journal of Pharmacological and Toxicological Methods|November 10, 2012
The impact of the site of blood sampling on pharmacokinetic parameters following sublingual dosing to dogsE Sohlberg, M M Halldin, A Annas, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1996
Metabolism and excretion of ropivacaine in humansM M Halldin, E Bredberg, B Angelin, et al.
Chemical Research in Toxicology|March 6, 2014
Pragmatic approaches to determine the exposures of drug metabolites in preclinical and clinical subjects in the MIST evaluation of the clinical development phaseJohanna Haglund, Magnus M Halldin, Asa Brunnström, et al.
JIMD Reports|February 23, 2013
Growth in Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase DeficiencyC Bieneck Haglind, M Halldin Stenlid, S Ask, et al.
European Journal of Clinical Pharmacology|February 14, 2024
ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokineticsBoel Nilsson, Johan Bylund, Magnus M Halldin, et al.
European Journal of Pain (London, England)|March 6, 2018
Clinical testing of three novel transient receptor potential cation channel subfamily V member 1 antagonists in a pharmacodynamic intradermal capsaicin modelE Sjögren, T Kullenberg, B Jonzon, et al.
Pharmacology|January 1, 1987
Pharmacokinetics and excretion of unique beta-adrenergic agonistsB L Ferraiolo, M M Halldin, Y Asscher, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Anesthesia and Analgesia|December 1, 1989
Disposition kinetics of ropivacaine in humansA Lee, D Fagan, M Lamont, et al.
Biochemical Pharmacology|October 1, 1985
Stimulation of pheomelanogenesis in cultured B16 melanoma cells by 4-tertiary butylcatecholT Kawashima, M M Halldin, K Fukuyama, et al.
Journal of Inherited Metabolic Disease|August 22, 2014
Increased and early lipolysis in children with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency during fastC Bieneck Haglind, A Nordenström, S Ask, et al.
Journal of Pharmacological and Toxicological Methods|November 10, 2012
The impact of the site of blood sampling on pharmacokinetic parameters following sublingual dosing to dogsE Sohlberg, M M Halldin, A Annas, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1996
Metabolism and excretion of ropivacaine in humansM M Halldin, E Bredberg, B Angelin, et al.
Chemical Research in Toxicology|March 6, 2014
Pragmatic approaches to determine the exposures of drug metabolites in preclinical and clinical subjects in the MIST evaluation of the clinical development phaseJohanna Haglund, Magnus M Halldin, Asa Brunnström, et al.
JIMD Reports|February 23, 2013
Growth in Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase DeficiencyC Bieneck Haglind, M Halldin Stenlid, S Ask, et al.
European Journal of Clinical Pharmacology|February 14, 2024
ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokineticsBoel Nilsson, Johan Bylund, Magnus M Halldin, et al.
European Journal of Pain (London, England)|March 6, 2018
Clinical testing of three novel transient receptor potential cation channel subfamily V member 1 antagonists in a pharmacodynamic intradermal capsaicin modelE Sjögren, T Kullenberg, B Jonzon, et al.
Pharmacology|January 1, 1987
Pharmacokinetics and excretion of unique beta-adrenergic agonistsB L Ferraiolo, M M Halldin, Y Asscher, et al.
Pageof 5